Royalty Pharma buys 1.5% royalty on Nuvalent's pipeline for up to $315M

Nuvalent, Inc.

• Royalty Pharma acquired a preexisting 1.5% net-sales royalty on neladalkib and zidesamtinib from an undisclosed third party.
• The deal value is up to $315 million; Nuvalent is not a party to the transaction.
• Nuvalent clarifies the 'low single digit preexisting royalty' is exactly 1.5% of net sales of both candidates.
• Nuvalent's revenue share agreement with its scientific founder remains unchanged.